Searched for: subject%3A%22Fibrinolysis%22
(1 - 20 of 115)

Pages

Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone
Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone
Development of a new test for the global fibrinolytic capacity in whole blood
Development of a new test for the global fibrinolytic capacity in whole blood
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: A systematic review
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: A systematic review
Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone
Inhibitors and activation markers of the haemostatic system during hormone therapy: A comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables
Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)
Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: Comparison of different assays
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: Comparison of different assays
Preeclampsia and its interaction with common variants in thrombophilia genes
Preeclampsia and its interaction with common variants in thrombophilia genes
Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2tu-PA)
Clot penetration and fibrin binding of amediplase, a chimeric plasminogen activator (K2tu-PA)
Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro
Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients
Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients
Time course of peritoneal tissue plasminogen activator after experimental colonic surgery: Effect of hyaluronan-based antiadhesive agents and bacterial peritonitis
Time course of peritoneal tissue plasminogen activator after experimental colonic surgery: Effect of hyaluronan-based antiadhesive agents and bacterial peritonitis
Adenovirus-mediated transfer of the 39 kD receptor-associated protein increases fibrinolytic capacity
Adenovirus-mediated transfer of the 39 kD receptor-associated protein increases fibrinolytic capacity
Oral, but not transdermal, administration of estrogens lowers tissue- type plasminogen activator levels in humans without affecting endothelial synthesis
Oral, but not transdermal, administration of estrogens lowers tissue- type plasminogen activator levels in humans without affecting endothelial synthesis
Acceleration of fibrinolysis by high-frequency ultrasound: The contribution of acoustic streaming and temperature rise
Acceleration of fibrinolysis by high-frequency ultrasound: The contribution of acoustic streaming and temperature rise
Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia
Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin
Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin
Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: Evidence for potently enhanced mannose receptor expression in mice
Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: Evidence for potently enhanced mannose receptor expression in mice
Searched for: subject%3A%22Fibrinolysis%22
(1 - 20 of 115)

Pages